The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 14, 2024
Filed:
Mar. 15, 2019
Applicant:
Intra-cellular Therapies, Inc., New York, NY (US);
Inventors:
Gretchen Snyder, New York, NY (US);
Robert Davis, San Diego, CA (US);
Lawrence P. Wennogle, Hillsborough, NJ (US);
Assignee:
INTRA-CELLULAR THERAPIES, INC., New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4985 (2006.01); A61K 9/00 (2006.01); A61K 31/13 (2006.01); A61K 31/135 (2006.01); A61K 31/137 (2006.01); A61K 31/138 (2006.01); A61K 31/155 (2006.01); A61K 31/165 (2006.01); A61K 31/197 (2006.01); A61K 31/343 (2006.01); A61K 31/36 (2006.01); A61K 31/38 (2006.01); A61K 31/381 (2006.01); A61K 31/42 (2006.01); A61K 31/485 (2006.01); A61K 31/55 (2006.01); A61K 31/5513 (2006.01); A61K 38/07 (2006.01); A61P 25/24 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4985 (2013.01); A61K 9/006 (2013.01); A61K 31/13 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/138 (2013.01); A61K 31/155 (2013.01); A61K 31/165 (2013.01); A61K 31/197 (2013.01); A61K 31/343 (2013.01); A61K 31/36 (2013.01); A61K 31/38 (2013.01); A61K 31/381 (2013.01); A61K 31/42 (2013.01); A61K 31/485 (2013.01); A61K 31/55 (2013.01); A61K 31/5513 (2013.01); A61K 38/07 (2013.01); A61P 25/24 (2018.01);
Abstract
The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.